Table 2.
Subgroup Analysis in RA
| Plasma Level Median (IQR) | ||||
|---|---|---|---|---|
|
| ||||
| Disease Characteristic and number of subjects | DPP4 (U/L) | P | FAP (pmol AMC/min/mL) | P |
| Rheumatoid factor | 0.48 | 0.11 | ||
| 54 Positive | 21.3 (9.4) | 1037.9 (668.9) | ||
| 19 Negative | 20.8 (12.3) | 788.7 (705.7) | ||
| Anti-CCP antibody | 0.27 | 0.18 | ||
| 50 Positive | 20.9 (10.4) | 1037.4 (688.9) | ||
| 19 Negative | 21.5 (10.7) | 842.5 (518.4) | ||
| Erosions on X-ray | 0.82 | 0.21 | ||
| 46 Present | 21.2 (9.8) | 1051.5 (685.5) | ||
| 23 Absent | 21.1 (13.6) | 913.4 (506.3) | ||
| Rheumatoid nodules | 0.33 | 0.50 | ||
| 20 Present | 20.9 (8.8) | 1013.2 (666.7) | ||
| 53 Absent | 21.4 (12.6) | 1037.4 (747.4) | ||
|
| ||||
| Treatment and number | ||||
|
| ||||
| Prednisone | 0.08 | 0.001 | ||
| 35 Yes | 20.0 (10.6) | 826.7 (455.4) | ||
| 38 No | 21.5 (12.0) | 1167.7 (627.1) | ||
| Methotrexate | 0.51 | 0.39 | ||
| 53 Yes | 20.9 (7.2) | 1018.8 (689.6) | ||
| 20 No | 23.8 (17.9) | 849.7 (796.0) | ||
| Leflunomide | 0.01 | 0.04 | ||
| 13 Yes | 16.2 (8.2) | 838.2 (310.5) | ||
| 60 No | 21.5 (10.6) | 1051.2 (701.9) | ||
| Sulfasalazine | 0.61 | 0.27 | ||
| 14 Yes | 20.9 (6.6) | 1085.8 (580.3) | ||
| 59 No | 21.2 (13.6) | 984.9 (741.1) | ||
| Hydroxychloroquine | 0.21 | 0.72 | ||
| 12 Yes | 20.4 (11.3) | 1101.9 (745.6) | ||
| 61 No | 21.2 (12.2) | 989.8 (700.7) | ||
| Biologic DMARD | 0.08 | 0.01 | ||
| 36 Yes | 22.6 (12.9) | 1081.3 (678.1) | ||
| 37 No | 20.7 (10.3) | 895.3 (734.7) | ||